Clinical trial
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have…
NCT00072852 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00072852 |
|---|---|
| Title | Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine |
| Official title | Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Irinotecan |
| Enrollment | 134 |
| Start date | Nov 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Nov 13, 2003 |
| Last update posted | Oct 16, 2008 |
| Countries | Argentina, Australia, Colombia, New Zealand, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: